GlassScriptPhysician profile
Benjamin Scott Reine
NPI 1922373935
$3,265.25
in general payments reported to CMS, 2019-2025
37 companies · $154 in 2025
The $154 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $639 · 2020: $342 · 2021: $838 · 2022: $611 · 2023: $488 · 2024: $194 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $836.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $835.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $536.16 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $460.52 | 2021-2024 | Freestyle Libre 3 |
| Abbvie INC. | $420.23 | 2021-2024 | |
| Pfizer INC. | $226.82 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $209.59 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.80 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $102.21 | 2022 | |
| Novo Nordisk INC | $97.11 | 2019-2023 | Wegovy |
| Lilly USA, LLC | $77.77 | 2019-2022 | |
| Daiichi Sankyo INC. | $77.21 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $76.54 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.06 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $70.49 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.59 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $50.47 | 2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $49.36 | 2019-2020 | |
| Antares Pharma, INC. | $46.90 | 2019 | |
| Horizon Therapeutics Plc | $44.41 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $42.40 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $39.58 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $37.51 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $34.70 | 2019 | |
| Genentech USA, INC. | $28.29 | 2019-2021 | |
| Shire North American Group INC | $27.41 | 2019 | |
| Sanofi Pasteur INC. | $25.44 | 2019-2022 | |
| Boston Scientific Corporation | $24.32 | 2025 | Watchman Flx |
| Amarin Pharma, INC. | $23.50 | 2020-2021 | |
| Astellas Pharma US INC | $20.23 | 2020 | |
| Dexcom, INC. | $15.14 | 2024 | Dexcom G6 Transmitter |
| Eisai INC. | $14.71 | 2020 | |
| Genzyme Corporation | $14.58 | 2022 | |
| Ironshore Pharmaceuticals INC. | $14.56 | 2019 | |
| Glaxosmithkline, LLC. | $13.31 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $11.54 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.40 | 2019 | |
| Mylan Specialty L.P. | $11.06 | 2019 | |
| Clarus Therapeutics INC. | $7.33 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Reine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.